

COPD: Von der Pathogenese zur Therapie

A. R. Koczulla, C. Vogelmeier

aus BDI aktuell 5/2008

- 1** Nocturnal Oxygen Therapy Trial Group. **Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial.** Ann Intern Med 1980; 93: 391–398
- 2** Barnes PJ, Stockley RA. **COPD: current therapeutic interventions and future approaches.** Eur Respir J 2005; 25: 1084–1106
- 3** Beeh KM, Derom E, Kanniss F et al. **Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.** Eur Respir J 2007; 29: 871–878
- 4** Churg A, Dai J, Tai H, Xie C, Wright JL. **Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown.** Am J Respir Crit Care Med 2002; 166: 849–854
- 5** Churg A, Wang RD, Tai H, Wang X, Xie C, Dai J, Shapiro SD, Wright JL. **Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release.** Am J Respir Crit Care Med 2003; 167: 1083–1089
- 6** Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. **Tumor necrosis factor-alpha drives 70 % of cigarette smoke-induced emphysema in the mouse.** Am J Respir Crit Care Med 2004; 170: 492–498
- 7** Cydulka RK, Emerman CL. **Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease.** Ann Emerg Med 1995; 25: 470–473
- 8** FM , Barbier D, Mege JL, Orehek J. **Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease.** Am J Respir Crit Care Med 1994; 150: 1453–1455
- 9** Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK. **Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.** Am J Respir Crit Care Med 2003; 168: 976–982
- 10** Glover ED, Laflin MT, Schuh KJ, Schuh LM, Nides M, Christen AG, Glover PN, Strnad JV. **A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers.** Addiction 2007; 102: 795–802
- 11** Gotfried MH. **Macrolides for the treatment of chronic sinusitis, asthma, and COPD.** Chest 2004; 125: 52S–60S
- 12** Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, Barnes PJ. **Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma.** Chest 2005; 128: 1974–1979
- 13** Healy DP. **Macrolide immunomodulation of chronic respiratory diseases.** Curr Infect Dis Rep 2007; 9: 7–13
- 14** Ishida W, Kajiwara T, Ishii M, Fujiwara F, Taneichi H, Takebe N, Takahashi K, Kaneko Y, Segawa I, Inoue H, Satoh J. **Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan.** Tohoku J Exp Med 2007; 212: 265–273
- 15** Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. **Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD.** Am J Respir Crit Care Med 1997; 155: 542–548
- 16** Laurell CB, Eriksson S. **Hypo-alpha-1-Antitrypsinämie.** Verh Dtsch Ges Inn Med 1964; 70: 537–539
- 17** Laurell CB, Eriksson S. **The serum alpha-1-antitrypsin in families with hypo-alpha-1-antitrypsinemia.** Clin Chim Acta 1965; 11: 395–398
- 18** Mahler DA, Huang S, Tabrizi M, Bell GM. **Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.** Chest 2004; 126: 926–934
- 19** Massaro GD, Massaro D. **Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats.** Nat Med 1997; 3: 675–677

- 20** Matera MG, Cazzola M. **Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?** *Drugs* 2007; 67: 503–515
- 21** Ong DE, Chytil F. **Changes in levels of cellular retinol- and retinoic-acid-binding proteins of liver and lung during perinatal development of rat.** *Proc Nat Acad Sci USA* 1976; 73: 3976–3978
- 22** Rennard SI, Fogarty C, Kelsen S et al. **The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 2007; 175: 926–934
- 23** Roth MD, Connett JE et al. **Feasibility of retinoids for the treatment of emphysema study.** *Chest* 2006; 130: 1334–1345
- 24** Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, Barnes PJ. **Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease.** *Am J Respir Cell Mol Biol* 2002; 26: 602–609
- 25** Smith SJ, Fenwick PS, Nicholson AG et al. **Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages.** *Br J Pharmacol* 2006; 149: 393–404
- 26** Soyseth V, Brekke PH, Smith P, Omland T. **Statin use is associated with reduced mortality in COPD.** *Eur Respir J* 2007; 29: 279–283
- 27** Steinberg MB, Foulds J. **Rimonabant for treating tobacco dependence.** *Vasc Health Risk Manag* 2007; 3: 307–311
- 28** van der Vaart H, Koeter GH, Postma DS et al. **First study of infliximab treatment in patients with chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 2005; 172: 465–469
- 29** Vestbo J, Hogg JC. **Convergence of the epidemiology and pathology of COPD.** *Thorax* 2006; 61: 86–88
- 30** Voelkel NF, Douglas IS, Nicolls M. **Angiogenesis in chronic lung disease.** *Chest* 2007; 131: 874–879
- 31** Vogelmeier C et al. **Guidelines for the Diagnosis and Therapy of COPD Issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin.** *Pneumologie* 2007; 61: 517–
- 32** Vogelmeier C, Koczulla R, Fehrenbach H, Bals R. **Pathogenese der chronisch obstruktiven Lungenerkrankung.** *Internist* 2006; 47: 885–892
- 33** Watz H, Kannies F, Magnussen H. **Neue pharmakologische Optionen in der Therapie der COPD.** *Pneumologie* 2007; 61: 365–373
- 34** Yao JS, Shen F, Young WL, Yang GY. **Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration.** *Neurochem Int* 2007; 50: 524–530
- 35** Zhen G, Park SW, Nguyenvu TL, Rodriguez MW, Barbeau R, Paquet AC, Erle DJ. **IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production.** *Am J Respir Cell Mol Biol* 2007; 36: 244–253
- 36** Schultz K, Bergmann KC, Kenn K et al. **Effektivität der pneumologischen Anschluss-Heilbehandlung (AHB).** *Dtsch Med Wochenschr* 2006; 131: 1793–1798
- 37** Schultz K, Taube K, Lang SM. **Stellenwert der COPD in der Langzeitrehabilitation bei COPD.** *Dtsch Med Wochenschr* 2007; 132: 508–512